Ballerup, Denmark

Claus Mathiesen


Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 15(Granted Patents)


Location History:

  • Veksø Sj., DK (2005)
  • Vekso, DK (2007)
  • Ballerup, DK (2007)

Company Filing History:


Years Active: 2005-2007

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations by Claus Mathiesen in Neuropharmacology

Introduction

Claus Mathiesen, an inventive mind based in Ballerup, Denmark, has significantly contributed to the field of neuropharmacology. With three patents to his name, Mathiesen’s work focuses on developing compounds that interact with the AMPA receptors, crucial for synaptic transmission in the brain.

Latest Patents

Among his notable inventions is the patent for "Compounds and their use as positive AMPA receptor modulators." This invention presents novel compounds characterized by a specific general formula, demonstrating their potential as positive modulators of the AMPA-receptor. Additionally, Claus has developed a patent titled "Benzothiazine derivatives, their preparation and use." This invention involves unique benzothiazine derivatives, which are beneficial as modulators of AMPA-sensitive glutamate receptors. These pharmaceutical compositions are poised to play a significant role in therapeutic applications.

Career Highlights

Claus Mathiesen is affiliated with Neurosearch A/S, a company dedicated to innovating solutions in neuropharmacology. His focused research and innovation in designing receptor modulators enhance the understanding and treatment of neurological disorders, marking significant progress in the field.

Collaborations

During his career, Mathiesen has collaborated with skilled professionals, including Thomas Varming and Tina Holm Johansen. This teamwork fosters an environment of innovation and contributes to the success of their shared projects, enhancing the impact of their research.

Conclusion

Claus Mathiesen's contributions to neuropharmacology through his patents reflect his dedication to advancing medical science. His work in developing compounds that target AMPA receptors is invaluable, potentially leading to breakthroughs in therapeutic practices for neurological conditions. As he continues to innovate at Neurosearch A/S, the implications of his research may resonate in the coming years, influencing the future of neuropharmacological treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…